Completed EARLY_PHASE1 INTERVENTIONAL 3-arm NCT03368352

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.

Sponsor: University of California, San Diego

Conditions Altitude Hypoxia Neurocognitive Dysfunction Oxidative Stress Sleep Ventilation

Updated 6 times since 2017 Last updated: Jan 29, 2019 Started: Jul 4, 2017 Primary completion: Dec 20, 2018 Completion: Dec 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Altitude Hypoxia and Neurocognitive Dysfunction and is currently completed. University of California, San Diego leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Jun 2018 — Feb 2019 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

Dec 2017 — Jun 2018 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of California, San Diego

Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States